Press Releases

4D Molecular Therapeutics Announces Collaboration to Advance Gene Therapies for Retinal Diseases with Oregon Health & Science University’s Casey Eye Institute and Oregon National Primate Research Center

Emeryville, CA – December 6, 2018 - 4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development today announced a research and development collaboration with the Casey Eye Institute ...

4D Molecular Therapeutics Announces FDA Orphan Drug Designation Granted to 4D-110 for the Treatment of Choroideremia

Emeryville, CA – November 16, 2018 - 4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development today announced that the U.S. Food and Drug Administration (FDA) has ...

4D Molecular Therapeutics to Participate at Upcoming Investor Conferences

Emeryville, CA – November 6, 2018 - 4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development today announced that company management will participate at the following upcoming investor ...

4D Molecular Therapeutics Raises $90 Million Series B Financing

- Proceeds advance proprietary next-generation Therapeutic Vector Evolution platform and pipeline of AAV gene therapy clinical candidates - - Lead product candidate 4D-110 in Choroideremia to enter clinic in 2019 - - Financing led by Viking Global Investors - Emeryville, ...

MedImmune and 4D Molecular Therapeutics Collaborate to Design, Develop and Commercialize AAV Gene Therapy for Chronic Lung Disease

July 10, 2018 Emeryville, Ca, USA — MedImmune, the global biologics research and development arm of AstraZeneca, and 4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development, today announced ...

4DMT and ROCHE Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy Products

Emeryville, CA, April 30, 2018 — 4D Molecular Therapeutics (4DMT), a leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development, today announced the expansion of its 2015 research agreement with F. Hoffmann-La Roche ...

4D Molecular Therapeutics Receives $3 Million Follow-On Funding from Cystic Fibrosis Foundation Therapeutics for Gene Therapy IND Candidate for Cystic Fibrosis

New Funding Brings Total IND-Enabling Research and Development Support for 4D-710 to over $3.5 Million Emeryville, CA — 4D Molecular Therapeutics (4DMT), a leader in adeno-associated virus (AAV) gene therapy vector discovery and product development, today announced $3 million in ...

4D Molecular Therapeutics and Foundation Fighting Blindness Partner to Develop Gene Therapies for Retinal Diseases

Emeryville, CA and Columbia, MD | July 24, 2017 — 4D Molecular Therapeutics (4DMT), a leader in adeno-associated virus (AAV) gene therapy vector discovery and product development, and the Foundation Fighting Blindness (FFB), the world’s largest non-governmental source of research funding ...

4D Molecular Therapeutics Enrolls First Patient in Natural History Study in Lead Clinical Program to Develop Gene Therapy Treatment for Choroideremia

Intravitreal delivery to the retina is critical to Choroideremia treatment Emeryville, CA | December 23, 2016 — 4D Molecular Therapeutics (4DMT), a leader in gene therapy product discovery and development, today announced the enrollment of the first participant in its ...

4D Molecular Therapeutics and the Choroideremia Research Foundation Partner to Develop Gene Therapy Treatment for Choroideremia

Intravitreal delivery to the retina is critical to Choroideremia treatment Emeryville, CA | February 23, 2016 — 4D Molecular Therapeutics (4DMT), a leader in Adeno-Associated Virus (AAV) gene therapy vector discovery and product development, and the Choroideremia Research Foundation (CRF), a ...

4D Molecular Therapeutics Announces Collaboration with Pfizer Inc. for Cardiac Gene Therapy Vector Discovery and Development

Leader in proprietary gene therapy vector discovery closes fifth partnership Emeryville, CA, Jan 7, 2016 — 4D Molecular Therapeutics (4DMT), a leader in Adeno-Associated Virus (AAV) gene therapy vector discovery and product development, today announced both an investment by and ...

Johnson & Johnson Innovation Announces Opening of the California Innovation Center

MENLO PARK, Calif. (June 5, 2013) – Johnson & Johnson Innovation today announced the opening of the Johnson & Johnson California Innovation Center, one of four regional hubs being established in the world’s leading life science innovation hotspots. A part ...